Compugen Ltd. Company Profile
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. Compugen's growing number of collaborations with major pharmaceutical and diagnostic companies cover both (i) the licensing of product candidates discovered by Compugen during the validation of its discovery platforms and in its internal research, and (ii) 'discovery on demand' agreements where existing or new Compugen discovery platforms are utilized to predict and select product candidates as required by a partner. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN), to utilize certain of the Company's 'in silica' predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at: www.cgen.com.
News Articles
MedImmune to Develop Compugen Immuno-Oncology Antibodies
AstraZeneca’s MedImmune subsidiary has agreed to exclusively license and develop bi-specific and multi-specific immuno-oncology antibody products from Compugen’s pipeline, through a collaboration ...
Compugen inks I-O deal worth over $210 million with AZ unit
Compugen has entered into an exclusive license agreement with MedImmune.
AZ signs up for access to Compugen’s pipeline
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
Compugen and MedImmune enter exclusive license agreement
MedImmune LLC and Compugen Ltd. penned an agreement for the development of bispecific and multi-specific antibody therapies for cancer.
Compugen and MedImmune Strike Oncology Development Deal Worth up to $200 million
Israel-based drug maker Compugen Ltd. and pharma giant AstraZeneca have teamed up to develop bi-specific and multi-specific immuno-oncology antibody products.
Compugen licenses Selexis cell line tech
Compugen has selected Selexisâ SUREtechnology cell expression platform to generate high-performance research cell banks (RCBs) and support its antibody pipeline.
Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the ...
Selexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for Compugen Read more...
MedImmune, Compugen sign immuno-oncology deal
Compugen has signed an exclusive license agreement with AstraZeneca’s subsidiary MedImmune for the development of bi-specific and multi-specific immuno-oncology antibody products.
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are b...
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen’s discovery efforts are based...
Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology ...
Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen Ltd. The company operates out of the MS Venturesâ Israe...
BioLineRx Ltd. and Compugen Ltd.
BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over curr...
More Information about "Compugen Ltd." on BioPortfolio
We have published hundreds of Compugen Ltd. news stories on BioPortfolio along with dozens of Compugen Ltd. Clinical Trials and PubMed Articles about Compugen Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Compugen Ltd. Companies in our database. You can also find out about relevant Compugen Ltd. Drugs and Medications on this site too.
